A possible pathogenic role of CD8+ T cells and their derived cytokine, IL-16, in SLE

Autoimmunity

Volumn 33, Issue 1, 2001, Pages 37-44

  Sekigawa, I ^a   Matsushita, M ^a   Lee, S ^a   Maeda, N ^a   Ogasawara, H ^a   Kaneko, H ^a   Iida, N ^a   Hashimoto, H ^a  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

CD4+ CD8+ T cell ratio; IL 16; Retrovirus; SLE; T cell activation

Indexed keywords

INTERLEUKIN 16;

HELPER CELL; HUMAN; LEUKOCYTE COUNT; NONHUMAN; PATHOGENESIS; RETROVIRUS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0035145021     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916930108994108     Document Type: Review

References (66)

1. Human immunodeficiency virus type-1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production
2. +T cell anergy
3. T lymphocytes, natural killer cells, cytokines, and immune regulation
4. + T cells in systemic lupus erythematosus: Alterations associated with prednisolone therapy
5. + T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus
6. Subsets of activated T cells in patients with systemic lupus erythematosus: The relation to cell cycle
7. + T cell ratio and T cell activation in systemic lupus erythematosus
8. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus
9. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus
10. Abnormalities in autologous mixed lymphocyte reaction-activated immunologic processes in systemic lupus erythematosus and their possible correction by interleukin 2
11. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus
12. + cells
13. Correlation on interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells
14. Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus
15. T lymphocyte subsets in systemic lupus erythematosus
16. Two distinct subsets of patients with systemic lupus erythematosus
17. Alteration in T cell subsets in active systemic lupus erythematosus
18. Phenotypes of T lymphocytes in systemic lupus erythematosus: Decreased cytotoxic/suppressor subpopulation is associated with deficient allogenic cytotoxic responses rather than with concanavalin A-induced suppressor cells
19. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody
20. + cells systemic lupus
21. +) in active systemic lupus erythematosus
22. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells
23. Impaired T-cell activation in patients with systemic lupus erythematosus
24. T lymphocytes from patients with systemic lupus erythematosus show increased response to interleukin-2 after costimulation with OKT3 monoclonal antibody and phorbol esters
25. Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28. Evidence for impaired T cell-accessory cell interaction
26. TCR zeta chain lacking exon 7 in two patients with systemic lupus erythematosus
27. Single-nucleotide polymorphisms of T cell receptor chain in patients with systemic lupus erythematosus
28. Characterization of lymphocytes that suppress IL-2 production in systemic lupus erythematosus
29. Partial purification of systemic lupus erythematosus-derived factors that suppress production of interleukin-2
30. Further characterization of interleukin-2 production by lymphocytes of patients with systemic lupus ertyhematosus
31. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation
32. Interleukin 16 and its function as a CD4 ligand
33. HIV suppression by interleukin-16
34. + cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression
35. IL-16 represses HIV-1 promoter activity
36. Interleukin-16 does not suppress HIV-1 replication in naturally infected peripheral blood mononuclear cells
37. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction
38. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation
39. + T cells
40. + T cells by IL-16 and IL-2
41. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen
42. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
43. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120
44. Circulating interleukin-16 in systemic lupus erythematosus
45. Suppression of systemic lupus erythematosus by the human immunodeficiency virus
46. SLE nephropathy in a patient with HIV infection: Case report and review of the literature
47. Renal manifestations of concurrent systemic lupus erythematosus and HIV infection
48. HIV infection and SLE: Their pathogenic relationship
49. Lupus, acquired immunodeficiency syndrome and antimalarial agents
50. The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus
51. + T cell ratio and IL-16 levels on treatment in SLE patients
52. The mechanism of action of cyclosporin A and FK506
53. Possible mechanism of the efficacy of low dose cyclosporine treatment for autoimmune disease
54. Retroviruses and autoimmune rheumatic disease
55. Retrovirus and systemic lupus erythematosus
56. Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells
57. Differences of HIV envelope protein between HIV-1 and HIV-2: Possible relationship to the lower virulence of HIV-2
58. The potential roles of endogenous retroviruses in autoimmunity
59. Nucleotide sequence of a full-length human endogenous retroviral segment
60. Detection of antibodies to recombinant gag protein derived from human endogenous retrovirus like sequence, clone 4-1, in autoimmune disease
61. Molecular mimicry between human endogenous retrovirus clone 4-1 and HLA class I antigen: With reference to the pathogenesis of systemic lupus erythematosus
62. Antigen recognition by class I-restricted T lymphocytes
63. Interaction of MHC class I molecules with the transporter associated with antigen processing
64. MHC ligands and peptide motifs: First listing
65. The 1982 revised criteria for the classification of systemic lupus erythematosus
66. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients